BTK Inhibitors for Managing Patients with B-Cell Malignancies: Safety and Optimal Use

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with hematologic malignancies.
Alexey Danilov, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.85 MB
Released: December 6, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Related Content

CCO printable treatment algorithm and toxicity management table to help optimize care of your patients with follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Released: September 30, 2020

Jacob D. Soumerai, MD, on how managing patients with CLL has evolved over the first 6 months of the COVID-19 pandemic, from Clinical Care Options (CCO)

person default Jacob D. Soumerai, MD Released: September 30, 2020

Commentary from David Marks, MD, PhD, on considerations for using blinatumomab vs inotuzumab ozogamicin in the treatment of relapsed/refractory ALL, from CCO

Released: September 30, 2020

Expert commentary from Danielle M. Brander, MD, on the implications of MRD evaluation in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue